Conference Coverage
S5-E20.2 – Drug Development Highlights From EASL Congress 2024: Tirzepatidate & Other “Twin-Cretins”
This conversation focuses on the tirzepatide late-breaker at the EASL Congress 2024 and broadens into a discussion of the other “Twin-cretins,” all of which are GLP-glucagon combinations.
S5-E20.1 – Drug Development Highlights from EASL Congress 2024: Resmetirom
This conversation from EASL Congress 2024 discusses some of the new research on resmetirom.
S5-E20 – Lessons from EASL Congress 2024: Exciting Advances in Drug Development
Naim Alkhouri and Mazen Noureddin join co-hosts Jörn Schattenberg and Roger Green to discuss the major drug development stories from the EASL Congress 2024.
S5-E19 – EASL Congress 2024: Interviews From a Seminal Meeting for MASLD & MASH
Roger Green conducts 1:1 interviews with Mike Betel, Louise Campbell and Sven Francque while they are at the EASL Congress 2024, discussing key issues related to MASLD
S5-E17.5 – Previewing EASL Congress 2024: Focusing on MASLD Drug Development
As the conversation wraps up, Jörn Schattenberg and Michelle Long discusses abstracts they will present at EASL Congress 2024, with Jörn focusing on new MASLD drug development and Michelle on an aggregation of studies sponsored by Novo Nordisk.
S5-E17.3 – Previewing EASL Congress 2024: Jörn Schattenberg Joins the MASLD Conversation
This conversation starts when co-host Jörn Schattenberg joins our EASL Congress 20224 preview. The episode itself focuses on the future of hepatology along with other MASLD abstracts and presentations.